Feb. 17, 2021
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for liver disease. The Company’s drug candidate, BIV201 (continuous infusion terlipressin), has an Orphan Drug designation for the treatment of refractory ascites, FDA Fast Track status, and US patent pending. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The active agent in BIV201, terlipressin, is approved for use in about 40 countries for the treatment of related complications of advanced liver cirrhosis but is not available in the US or Japan. The FDA has never approved terlipressin. BioVie is targeting this landmark achievement. Visit BIVIinfo.com to learn more.
Bloomberg TV Show
CEO Interviews
"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."
1-800-REDCHIP (733-2447) | 431 E Horatio Ave, Suite #100, Maitland, FL 32751
"Discovering Tomorrow's Blue Chips Today." ® | Home | Contact | Privacy Policy | Disclosures
© 2024 RedChip Companies, Inc.